Ruban, M., Bolotina, L., Kaprin, A. (2026). Efficacy and safety of a short-course (12-week) de-escalated neoadjuvant regimen (weekly paclitaxel/trastuzumab/pertuzumab) in early HER2-positive breast cancer: Interim analysis of a prospective study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.599